Uptake Medical said it’s InterVapor targeted vapor therapy system has been used in the 1st-ever regional lung cancer tumor ablation procedure.
The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the company said.
The patient treated with the system was diagnosed with colorectal cancer that metastasized to the lung. The procedure was performed by Dr. Arschang Valipour at Vienna’s Otto-Wagner-Spital Hospital, Tustin, Calif.-based Uptake said.
“InterVapor is the only therapy with the promise of quick, simple, complete bronchoscopic ablation of lung tumor with margin. The vapor followed the patient’s anatomical boundaries and we successfully completed this first-in-human case without penetrating the tumor or puncturing adjacent healthy tissues, while creating a well-defined and controlled margin within the lung,” Valipour said in a press release.
The procedure took approximately 10 minutes, and Uptake Medical reported that there was a 90% successful ablation of the tumor itself. Tumor death was projected within 3 days following the procedure.
“Current treatment options for lung cancer often require patients to undergo invasive surgery or tolerate toxic chemicals. We are very encouraged by the initial clinical results from InterVapor’s 1st-in-human case, and hope that regional tumor ablation performed with vapor will ultimately represent a new hope as a treatment option for the thousands of people worldwide who are battling lung cancer,” CEO King Nelson said in a press release.
Earlier this month, Uptake Medical said data from a clinical study of its InterVapor device showed significant improvements in lung function and quality of life in patients treated with the device.
The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the Tustin, Calif.-based company said.